Merck Crecimiento futuro

Future controles de criterios 4/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Merck de 26.3% y 5.2% por año respectivamente. Se prevé que el BPA crezca en un 25.3% al año. Se espera que la rentabilidad financiera sea de 38.8% en 3 años.

Información clave

24.9%

Tasa de crecimiento de los beneficios

24.0%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	23.6%
Tasa de crecimiento de los ingresos	5.5%
Rentabilidad financiera futura	38.7%
Cobertura de analistas	Good
Última actualización	03 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Merck: One Of The Best - Unveiling The Trifecta Of Safety, Dividends, And Growth

Dec 25

Previsiones de crecimiento de beneficios e ingresos

NYSE:MRK - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	72,649	24,746	25,211	26,696	20
12/31/2025	68,598	22,267	23,321	24,820	24
12/31/2024	64,108	19,510	18,477	24,336	24
3/31/2024	61,403	2,306	11,040	14,757	N/A
12/31/2023	60,115	365	9,143	13,006	N/A
9/30/2023	59,315	4,608	13,167	17,190	N/A
6/30/2023	58,311	3,111	10,828	15,075	N/A
3/31/2023	57,869	13,030	11,262	15,673	N/A
12/31/2022	59,283	14,519	14,707	19,095	N/A
9/30/2022	58,974	15,322	15,249	19,696	N/A
6/30/2022	57,169	16,641	14,398	18,891	N/A
3/31/2022	53,978	13,910	12,870	17,220	N/A
12/31/2021	48,704	12,345	9,661	14,109	N/A
9/30/2021	46,131	5,908	8,401	13,072	N/A
6/30/2021	43,906	3,665	6,953	11,897	N/A
3/31/2021	41,857	4,793	6,659	11,184	N/A
12/31/2020	41,518	4,519	5,812	10,241	N/A
9/30/2020	42,438	9,492	6,906	11,041	N/A
6/30/2020	43,906	9,070	7,996	11,645	N/A
3/31/2020	46,312	9,399	8,947	12,811	N/A
12/31/2019	39,121	5,690	10,071	13,440	N/A
9/30/2019	45,970	9,314	8,973	12,238	N/A
6/30/2019	44,367	9,362	7,846	10,805	N/A
3/31/2019	43,073	8,399	8,343	11,103	N/A
12/31/2018	42,294	6,220	8,307	10,922	N/A
9/30/2018	41,729	3,347	8,948	11,349	N/A
6/30/2018	41,259	1,341	5,196	7,385	N/A
3/31/2018	40,725	1,579	5,321	7,320	N/A
12/31/2017	40,122	2,394	N/A	6,451	N/A
9/30/2017	39,804	2,845	N/A	6,064	N/A
6/30/2017	40,016	5,086	N/A	10,206	N/A
3/31/2017	39,929	4,346	N/A	8,489	N/A
12/31/2016	39,807	3,920	N/A	10,376	N/A
9/30/2016	39,907	5,492	N/A	10,990	N/A
6/30/2016	39,444	5,133	N/A	11,330	N/A
3/31/2016	39,385	4,614	N/A	12,427	N/A
12/31/2015	39,498	4,442	N/A	12,538	N/A
9/30/2015	39,765	10,781	N/A	7,128	N/A
6/30/2015	40,249	9,850	N/A	8,165	N/A
3/31/2015	41,398	11,168	N/A	7,783	N/A
12/31/2014	42,237	11,920	N/A	7,989	N/A
9/30/2014	43,075	5,385	N/A	12,050	N/A
6/30/2014	43,550	5,614	N/A	11,651	N/A
3/31/2014	43,626	4,516	N/A	11,674	N/A
12/31/2013	44,033	4,404	N/A	11,654	N/A
9/30/2013	44,450	4,531	N/A	10,437	N/A
6/30/2013	44,907	5,136	N/A	9,627	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (26.3% al año) de MRK es superior a la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Se prevé que los beneficios (26.3% al año) de MRK crezcan más rápidamente que el mercado US (14.7% al año).

Beneficios de alto crecimiento: Se espera que los beneficios de MRK crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (5.2% al año) de MRK crezcan más despacio que el mercado de US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 5.2% al año) de MRK crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de MRK sea alta dentro de 3 años (38.8%)

Merck Crecimiento futuro

Future controles de criterios 4/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Merck & Co., Inc. Provides Earnings Guidance for Full-Year 2024

Consensus EPS estimates fall by 16%

Recent updates

Insider exercised options to buy US$1.8m worth of stock.

Merck Q1: There's Still Room For Growth

Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival as First-Line Treatment in Patients with HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Merck & Co., Inc. Provides Earnings Guidance for Full-Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Merck Earnings Preview: Not Much To Fear, Plenty To Look Forward To

We Think Merck (NYSE:MRK) Can Stay On Top Of Its Debt

Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA®? (pembrolizumab) for First-Line Treatment of Certain Patients with Metastatic Non-Small Cell Lung Cancer

Merck: Better Times Ahead On Approvals And Outlook

European Commission Approves Merck’s Keytruda® (Pembrolizumab) Plus Chemotherapy

Merck's Future Brightens With Winrevair's Blockbuster Potential

Merck Provides Update on Phase 3 Keylynk-006 Trial Evaluating Keytruda® (Pembrolizumab) Plus Maintenance Lynparza® (Olaparib) for Certain Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer

Merck Announces Positive Data on V116, Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults

Merck Announces its KEYTRUDA Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival Versus CRT Alone in Patients with Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

Merck Announces Plans to Conduct Clinical Trials of A Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9

IDEAYA Biosciences, Inc. Announces Clinical Collaboration to Evaluate Ide161 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Endometrial Cancer

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Upcoming dividend of US$0.77 per share

Merck: A High-Conviction Investment For Long-Term Growth

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence

Merck & Co., Inc., Annual General Meeting, May 28, 2024

FDA Grants Priority Review to Merck's Application for Keytruda (Pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma

Health Canada Approves Keytruda® in Combination with Trastuzumab and Chemotherapy, as A First-Line Treatment for Patients with Locally Advanced Her2-Positive Gastric or Gastric or Gastroesophageal Junction Adenocarcinoma

Insider notifies of intention to sell stock

Insider exercised options and sold US$1.7m worth of stock

Executive VP & General Counsel recently sold US$3.8m worth of stock

Full year 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 16%

Merck: Big Pharma Looks Stronger Than Ever Ahead Of 2023 Earnings

Merck Announces Results from the Phase 3 AMBASSADOR (A031501/KeyNOTE-123 Trial Evaluating KEYTRUDA

Third quarter dividend of US$0.77 announced

Is Merck & Co., Inc. (NYSE:MRK) Trading At A 47% Discount?

Merck Declares Dividend for the Second Quarter of 2024, Payable on April 5, 2024

Merck & Co., Inc. Announces FDA Approves Merck's KEYTRUDA® (Pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients with FIGO 2014 Stage III-IVA Cervical Cancer

Merck Reportedly in Talks to Buy Harpoon Therapeutics

Merck's Soaring Stock: Examining The Euphoria Amidst Potential Pitfalls

Merck & Co., Inc. Announces Phase 3 Trial Initiations for Four Investigational Candidates from Its Promising Hematology and Oncology Pipeline

Merck: One Of The Best - Unveiling The Trifecta Of Safety, Dividends, And Growth

FDA Grants Priority Review to Merck's New Biologics License Application for V116

Merck Announces FDA Approves Expanded Indication for KEYTRUDA (pembrolizumab) Plus Padcev for the First-Line Treatment of Adult Patients with Locally Advanced or Metastatic Urothelial Cancer

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento